Is GANX or LPCN more profitable?

Gain Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Lipocine -571.18% -66.70% -59.39%

Does the media favor GANX or LPCN?

In the previous week, Gain Therapeutics had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Lipocine. Lipocine's average media sentiment score of 0.34 beat Gain Therapeutics' score of 0.00 indicating that Lipocine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate LPCN or AIFC?

Lipocine currently has a consensus target price of $15.00, suggesting a potential upside of 597.67%. Given Lipocine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Lipocine is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, LPCN or AIFC?

Lipocine has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 8.95 -$9.63M -$1.88 N/A ALT5 Sigma $24.84M 3.20 -$344.51M N/A N/A

Is LPCN or AIFC more profitable?

Lipocine has a net margin of -571.18% compared to ALT5 Sigma's net margin of -2,483.94%. Lipocine's return on equity of -66.70% beat ALT5 Sigma's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -571.18% -66.70% -59.39% ALT5 Sigma -2,483.94% -68.25% -62.43%

Does the media refer more to LPCN or AIFC?

In the previous week, Lipocine had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for ALT5 Sigma. Lipocine's average media sentiment score of 0.34 beat ALT5 Sigma's score of 0.00 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, TLPH or LPCN?

Lipocine has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talphera $30K 2,231.70 -$14.29M -$0.31 N/A Lipocine $1.98M 8.95 -$9.63M -$1.88 N/A

Is TLPH or LPCN more profitable?

Talphera has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -92.98% -53.22% Lipocine -571.18% -66.70% -59.39%

Which has stronger valuation & earnings, LPCN or IBIO?

Lipocine has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 8.95 -$9.63M -$1.88 N/A iBio $300K 226.87 -$18.38M -$0.58 N/A

Is LPCN or IBIO more profitable?

iBio has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. iBio's return on equity of -53.86% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -571.18% -66.70% -59.39% iBio N/A -53.86% -46.48%

Does the media refer more to LPCN or IBIO?

In the previous week, Lipocine and Lipocine both had 2 articles in the media. iBio's average media sentiment score of 1.05 beat Lipocine's score of 0.34 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lipocine (LPCN) Competitors

$2.15 -0.08 (-3.59%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$2.16 +0.01 (+0.47%)

As of 07/20/2026 07:34 PM Eastern

Compare

LPCN vs. GANX, CYPH, AIFC, TLPH, and IBIO

Should you buy Lipocine stock or one of its competitors? MarketBeat compares Lipocine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipocine include Gain Therapeutics (GANX), Cypherpunk Technologies (CYPH), ALT5 Sigma (AIFC), Talphera (TLPH), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry.

How does Lipocine compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Gain Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Lipocine	-571.18%	-66.70%	-59.39%

In the previous week, Gain Therapeutics had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Gain Therapeutics and 2 mentions for Lipocine. Lipocine's average media sentiment score of 0.34 beat Gain Therapeutics' score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lipocine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lipocine has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,390.39	-$20.16M	-$0.58	N/A
Lipocine	$1.98M	8.95	-$9.63M	-$1.88	N/A

Gain Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 360.12%. Lipocine has a consensus price target of $15.00, indicating a potential upside of 597.67%. Given Lipocine's higher probable upside, analysts plainly believe Lipocine is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Gain Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 4.7% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Lipocine beats Gain Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Lipocine compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

In the previous week, Lipocine had 2 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for Cypherpunk Technologies. Lipocine's average media sentiment score of 0.34 beat Cypherpunk Technologies' score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
Cypherpunk Technologies	Neutral
Lipocine	Neutral

Cypherpunk Technologies has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Cypherpunk Technologies' return on equity of -48.33% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Lipocine	-571.18%	-66.70%	-59.39%

Cypherpunk Technologies has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Cypherpunk Technologies presently has a consensus target price of $0.90, indicating a potential upside of 25.54%. Lipocine has a consensus target price of $15.00, indicating a potential upside of 597.67%. Given Lipocine's higher possible upside, analysts clearly believe Lipocine is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by company insiders. Comparatively, 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cypherpunk Technologies has higher earnings, but lower revenue than Lipocine. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Lipocine	$1.98M	8.95	-$9.63M	-$1.88	N/A

Summary

Cypherpunk Technologies and Lipocine tied by winning 7 of the 14 factors compared between the two stocks.

How does Lipocine compare to ALT5 Sigma?

Lipocine (NASDAQ:LPCN) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 4.7% of Lipocine shares are held by insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lipocine had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for ALT5 Sigma. Lipocine's average media sentiment score of 0.34 beat ALT5 Sigma's score of 0.00 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lipocine has a net margin of -571.18% compared to ALT5 Sigma's net margin of -2,483.94%. Lipocine's return on equity of -66.70% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Lipocine has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	8.95	-$9.63M	-$1.88	N/A
ALT5 Sigma	$24.84M	3.20	-$344.51M	N/A	N/A

Lipocine has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

Lipocine currently has a consensus target price of $15.00, suggesting a potential upside of 597.67%. Given Lipocine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Lipocine is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lipocine beats ALT5 Sigma on 12 of the 14 factors compared between the two stocks.

How does Lipocine compare to Talphera?

Talphera (NASDAQ:TLPH) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Lipocine had 2 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for Talphera. Lipocine's average media sentiment score of 0.34 beat Talphera's score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Neutral
Lipocine	Neutral

Talphera has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Talphera has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Lipocine	-571.18%	-66.70%	-59.39%

Talphera currently has a consensus price target of $3.00, indicating a potential upside of 132.56%. Lipocine has a consensus price target of $15.00, indicating a potential upside of 597.67%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

37.7% of Talphera shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 4.7% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lipocine has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	2,231.70	-$14.29M	-$0.31	N/A
Lipocine	$1.98M	8.95	-$9.63M	-$1.88	N/A

Summary

Lipocine beats Talphera on 10 of the 17 factors compared between the two stocks.

How does Lipocine compare to iBio?

Lipocine (NASDAQ:LPCN) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 4.7% of Lipocine shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Lipocine and Lipocine both had 2 articles in the media. iBio's average media sentiment score of 1.05 beat Lipocine's score of 0.34 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lipocine has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, iBio has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Lipocine presently has a consensus price target of $15.00, indicating a potential upside of 597.67%. iBio has a consensus price target of $5.00, indicating a potential upside of 264.96%. Given Lipocine's higher probable upside, analysts clearly believe Lipocine is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

iBio has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. iBio's return on equity of -53.86% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
iBio	N/A	-53.86%	-46.48%

Lipocine has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	8.95	-$9.63M	-$1.88	N/A
iBio	$300K	226.87	-$18.38M	-$0.58	N/A

Summary

iBio beats Lipocine on 10 of the 16 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LPCN vs. The Competition

Export

Metric	Lipocine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.39M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-1.15	20.20	27.07	23.95
Price / Sales	8.95	340.68	515.05	90.33
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.82	4.20	10.62	6.14
Net Income	-$9.63M	$65.94M	$3.60B	$331.74M
7 Day Performance	-6.93%	-3.05%	-1.26%	-1.82%
1 Month Performance	-7.73%	-1.30%	1.07%	-1.45%
1 Year Performance	-32.18%	15.22%	23.63%	16.32%

Lipocine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LPCN Lipocine	2.8139 of 5 stars	$2.15 -3.6%	$15.00 +597.7%	-31.1%	$18.39M	$1.98M	N/A	10	Analyst Upgrade
GANX Gain Therapeutics	2.7706 of 5 stars	$1.68 -4.5%	$7.50 +346.4%	+2.8%	$75.07M	$50K	N/A	20	News Coverage Positive News
CYPH Cypherpunk Technologies	1.7992 of 5 stars	$0.73 +4.7%	$0.90 +23.0%	+108.4%	$74.39M	N/A	N/A	40
AIFC ALT5 Sigma	0.1498 of 5 stars	$0.54 +1.5%	N/A	-92.2%	$74.15M	$24.84M	N/A	170
TLPH Talphera	2.5664 of 5 stars	$1.41 -1.1%	$3.00 +113.5%	+214.7%	$73.70M	$30K	N/A	19

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LPCN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipocine (LPCN) Competitors

LPCN vs. GANX, CYPH, AIFC, TLPH, and IBIO

How does Lipocine compare to Gain Therapeutics?

Summary

How does Lipocine compare to Cypherpunk Technologies?

Summary

How does Lipocine compare to ALT5 Sigma?

Summary

How does Lipocine compare to Talphera?

Summary

How does Lipocine compare to iBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lipocine (LPCN) Competitors

LPCN vs. GANX, CYPH, AIFC, TLPH, and IBIO

How does Lipocine compare to Gain Therapeutics?

Is GANX or LPCN more profitable?

Does the media favor GANX or LPCN?

Which has stronger earnings and valuation, GANX or LPCN?

Do analysts recommend GANX or LPCN?

Which has more volatility and risk, GANX or LPCN?

Do insiders & institutionals believe in GANX or LPCN?

Summary

How does Lipocine compare to Cypherpunk Technologies?

Does the media favor CYPH or LPCN?

Is CYPH or LPCN more profitable?

Which has more risk and volatility, CYPH or LPCN?

Do analysts rate CYPH or LPCN?

Do institutionals and insiders hold more shares of CYPH or LPCN?

Which has better earnings & valuation, CYPH or LPCN?

Summary

How does Lipocine compare to ALT5 Sigma?

Do institutionals and insiders have more ownership in LPCN or AIFC?

Does the media refer more to LPCN or AIFC?

Is LPCN or AIFC more profitable?

Which has stronger valuation & earnings, LPCN or AIFC?

Which has more volatility and risk, LPCN or AIFC?

Do analysts rate LPCN or AIFC?

Summary

How does Lipocine compare to Talphera?

Does the media prefer TLPH or LPCN?

Which has more risk & volatility, TLPH or LPCN?

Is TLPH or LPCN more profitable?

Do analysts rate TLPH or LPCN?

Do institutionals & insiders believe in TLPH or LPCN?

Which has stronger valuation & earnings, TLPH or LPCN?

Summary

How does Lipocine compare to iBio?

Do insiders & institutionals hold more shares of LPCN or IBIO?

Does the media refer more to LPCN or IBIO?

Which has more volatility and risk, LPCN or IBIO?

Do analysts prefer LPCN or IBIO?

Is LPCN or IBIO more profitable?

Which has stronger valuation & earnings, LPCN or IBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools